Table 1.
Medical data of PML patients stratified for seizures and PAT.
| PML + seizure | PML – seizure | p value | PAT | No PAT | p value | |
|---|---|---|---|---|---|---|
| Female | 62.5% | 57.1% | 1.0* | 66.7% | 55.6% | 1.0* |
| Age (years) | 38 (SD 5.5) | 41 (SD 8.2) | 0.4$ | 38 (SD 5.4) | 41 (SD 7.8) | 0.6$ |
| Age at MS onset (years) | 27 (SD 8) | 28 (SD 6) | 0.5$ | 29 (SD 5.6) | 27 (SD 7.9) | 0.5$ |
| Mean number of immunosuppressive pretreatment | 1.1 (SD 0.6) | 1.4 (0.5) | 0.5$ | 1.3 (SD 0.5) | 1.2 (SD 0.7) | 1.0$ |
| Duration of natalizumab therapy (years) | 3 (SD 0.9) | 3.1 (SD 1.6) | 0.9$ | 4 (SD 1.4) | 3 (SD 1.1) | 0.3$ |
| Mean number of natalizumab infusions | 33 (SD 8.2) | 36 (SD 14.8) | 0.6$ | 40 (SD 11.7) | 31 (SD 10.2) | 0.09$ |
| PML therapy with mefloquine | 87.5% | 100% | 1.0* | 100% | 88.9% | 1.0* |
| PML therapy with mirtazapine | 75% | 100% | 0.5* | 100% | 77.8% | 0.5* |
*
2-sided Fisher’s exact test; $ Mann–Whitney test.
MS, multiple sclerosis; PAT, preventive antiepileptic treatment; PML, progressive multifocal leukoencephalopathy; SD, standard deviation.